Reading CV? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CV free→CapsoVision, Inc. (CV)
NASDAQHealth CareMedical DevicesSnapshot 2026-07-06
Watch· this week
$6.61-9.20%
Close 2026-07-06 · 1-day change
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
The bottom line
The thesis is that CV's growth potential is uncertain due to weak recent performance. The company has not been profitable over the past year, which raises concerns. CV trades at a valuation that appears expensive. Peer multiples imply a price about 340% below where it trades. If CV cuts guidance on the next call, that could negatively impact the stock. This read is provisional.
as of 2026-07-06
Quick facts
- Exchange
- NASDAQ
- Sector
- Health Care
- Industry
- Medical Devices
- Market cap
- $363.74M
- Employees
- —
- IPO date
- 2025-05-09
- Next earnings
- 2026-08-13
Price
Daily closes. Earnings/event dots are placed inline.
Adjusted daily closes (split & dividend). Scroll over the chart to zoom; click a range to reset.
EarningsMaterial event
What's priced in
(what the market already expects)What it's worth (estimated)
A consensus fair price across 2 valuation methods, at three horizons. Current price $6.61. As of 2026-07-06. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Fair value· primary
$1.49
Range $1.14 – $1.83
vs price: +344% above
Method agreement : high · 2 methods
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
3-year
$2.25consensus
Range $1.76 – $2.74
vs price: +194% above
Method agreement : medium · 2 methods
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
5-year
$2.25consensus
Range $1.76 – $2.74
vs price: +194% above
Method agreement : medium · 2 methods
A long-thesis check that carries the widest uncertainty of the three horizons.
How this stock is priced
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Long-term · 1–3 yr
12-month view
Trading +344% versus the 12-month peer-multiple consensus (looks stretched on this basis).
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Compared to peers
23.1xP/S · peer median 2.8x
Looks more expensive than peers.
Compared to its own history
Self-history needs ~20 months of data.
P/E
—
EV/EBITDA
—
FCF yield
-7.7%
How strong is the business
(quality & execution)Factor signals
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Recent financial performance
Not enough signal yet.
Earnings quality
Not enough signal yet.
Macro sensitivity
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, Fed net liquidity, long-term interest rates, real (inflation-adjusted) rates.
Management & capital allocation
neutral9 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated neutral grew net income 50% of the time over the next year (vs 48% for the rest of the cohort, n=4965).
51st pctl · Health Care
Not investment advice. As of 2026-07-06.
Earnings setup & market context
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
Earnings setup · pre-print positioning
forward-looking
BullishEPS revised -4.3% / 30d, n=1for period ending 2026-09-30
Why this setup
Consensus revisions
EPS estimate $-0.12 → $-0.12 (-4.3% / 30d). 1 raised, 0 cut, 1 covering analysts.
Rating actions
0 upgrades, 0 downgrades / 30d. 100% of analysts rate Buy.
Material events
0 positive, 0 negative / 30d.
Sector context
Intermediate · WeeklySector phase: health care is in maturing, with decelerating (~0.5 years in phase).
Sector regime (90d momentum): headwind.Secular epoch: by revenue growth.Management scorecard
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Long-term · 1–3 yr
Provisional
- Earnings discipline
- weak
- Post-call reaction
- weak
A guidance track record builds as the company issues and delivers on guidance.
as of 2026-07-06
What management is focused on
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Long-term · 1–3 yr
How bumpy is the path
(risk while you hold it)Risk: how this stock moves
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
Intermediate · WeeklyLong-term · 1–3 yr
On a typical day, $10k can swing ±$266.
How much price usually moves either way.
On a bad day, this stock has moved -$980.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $6,782.
Deepest peak-to-trough drop in the last year.
elevatedas of 2026-07-06
Past results, not a forecast. Not investment advice.
What would change the read
(catalysts & re-read triggers)What changed
The most important moves since the prior daily snapshot.
Short-term · Daily
- label change · signal_labelsmall change
Signal changed from 'None' to 'cautious'.
No, our read on the company is unchanged. There are no new strengths or weaknesses. The company remains unprofitable, and there is insufficient recent financial performance to assess its thesis. The market backdrop shows mixed movements, with some sectors rising while others fall.
as of 2026-07-06
What to watch next
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Intermediate · Weekly
- UpsideMedium confidenceMonthsactive 17d
Watch for updates on the $14M private placement
Why it matters: Raising this capital is crucial for funding operations and growth initiatives. Failure to raise funds could limit progress.
What confirms / what disproves
Confirms:Successful completion of the private placement by the end of Q3 2026.
Disproves:Failure to secure the $14M in private placement funding by the end of Q3 2026.
Management priorities
News catalysts
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
- 2026-05-141mo agoSeeking Alpha
Advances: Develop CapsoCam Colon
AI-assisted reading clearance supports product development.
Strongly reinforcesUnconfirmed report
This sector is also watching
- Watch for Health Care revenue growth to re-accelerate above 10%
What could change this view
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Intermediate · Weekly
Upside triggers
- If sector bellwethers like ABT, SYK, and MDT keep beating earnings and guiding higher, the Healthcare sector momentum should keep lifting CV and other Healthcare names. Worth watching these names for early signals.
- If CV raises forward guidance on the next earnings call (currently NEW as of 2026-03-20), that's a momentum boost. Street estimates typically follow guidance up and the stock tends to re-rate higher.
Downside triggers
- If CV cuts guidance on the next call (currently NEW as of 2026-03-20), that's a meaningful negative. The Street tends to walk down estimates and the stock usually takes a leg lower.
- If sector bellwethers like ABT, SYK, and MDT start missing or guiding lower, the Healthcare tailwind helping CV and other Healthcare names could fade. Watch these names for early warning.
- If CV misses again next quarter like this past one (a solid miss of -15% on the 2026-03-31 print), expect continued pressure. The Street usually keeps walking estimates down after consecutive misses.
Recent events
(material 8-K / filing activity)Material updates
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
- 2026-07-025d agoItem 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Dr. David S. Shields as a Director On July 1, 2026, the Board of Directors (the “Board”) of CapsoVision Inc. (the “Company”) appointed Dr. David Stanley Shields to serve as a Class I director of the Board and as a member of the Compensation Committee of the Board, in each case effective immediately to fill the vacancy upon the resign…
Executive changeneutral
Score history
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not enough history for a weekly changelatest as of 2026-07-06
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.